Current therapy and future prospects in lymphoma

References

• Harris NL, Jaffe ES, Stein H et al. A revisedEuropean-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. B/ooc/84, 1361–1392 (1994).
   Google Scholar
• Harris NL, Jaffe ES, Diebold J et al. The Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10, 1419–1432 (1999).
   Google Scholar
• •• This paper is a report of the WHO project of reclassification of lymphomas. The WHO adopted the Revised European American Classification of Lymphoid Neoplasms (REAL), which is based on a combination of morphological, imrnunophenotypic, genetic and clinical features.
   Google Scholar
• Shipp MA, Harrington DP et al. A model for aggressive non-Hodgkin's lymphoma. The International -Hodgkin's Lymphoma Prognostic Factors Project [see comments] N Eng/. Med. 329, 987–994 (1993).
   Google Scholar
• •• In an attempt to create a prognostic model for NHL, Shipp et al., identified 2031 patients with aggressive NHL from 16 institutions and cooperative groups in the United States, Europe and Canada They identified four risk groups based on age, tumour stage, serum lactate dehydrogenase concentration, performance status and number of extra-nodal sites. The predicted survival in the four groups were 73, 51,43 and 26%, respectively.
   Google Scholar
• Glick JH, Kim K, Earle J, O'Connell MJ. ECOG randomised Phase III trial of CHOP vs. CHOP + radiotherapy for intermediate grade early stage non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol 14,391 (1995).
   Google Scholar
• •• Glick et al., randomized 345 patients with -stageaggressive NHLbetween eight courses of CHOP or eight courses of CHOP followed by involved field radiotherapy. The authors report a significantly longer failure-free survival in the radiotherapy arm (73 vs. 58%), and a prolonged overall survival (84 vs. 70%) although this did not reach statistical significance.
   Google Scholar
• Miller TP, Dahlberg S, Cassady JR etal. alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma [see comments]. N Engl. I Med. 339,21-26 (1998). 401 patients with limited stage (I—I) aggressive NHL were randomised to receive either eight courses of CHOP or three courses of CHOP followed by involved field radiotherapy. Miller et aL found that both progression-free survival and overall survival were significantly improved in the radiotherapy arm (77 vs. 64% and 82 vs. 72%).
   Google Scholar
• Brusamolino E, Lunghi F, Orlandi E etal. of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. I-Lematologica 85 (10), 1032 — 1039 (2000).
   Google Scholar
• Klasa R, Connors J, Fairey R. Treatment of stage Hodgkin's disease: Improved outcome with brief chemotherapy and radiotherapy without staging laparotomy. Ann. Oncol 7,10 (1996).
   Google Scholar
• Santoro A, Bonfante V, Viviani S et al. nodal versus involved field irradiation after 4 cycles of ABVD in early stage Hodgkin's disease. Proc. Am. Soc. an. Oncol 15,415 (1996).
   Google Scholar
• Canellos GP, Anderson JR, Propert KJ et al. of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl. I Med. 327(21), 1478–1484 (1992).
   Google Scholar
• Bonfante V, Santoro A, Viviani S, Valagussa, Bonadonna G. ABVD in the treatment of Hodgkin's disease. Semin. Oncol 19(2 Suppl. 5), 38–44 (1992).
   Google Scholar
• Horning SJ, Williams J, Bartlett NL et al. of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Co-operative Oncology Group pilot study E1492.1 Clin. Oncol 18,972–980 (2000).
   Google Scholar
• •In this Phase 11 study, Homing and co-workers treated 47 patients with advanced stage Hodgkin's disease, with 12 weeks of the multidrug regimen Stanford V followed by consolidation radiotherapy to nodal masses greater than 5 cm. The overall survival was 96% at 2 and 5 years.
   Google Scholar
• Diehl V, Franklin J, Hasenclever D et al., a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. j Clin. Oncol 16,3810–3821 (1998).
   PubMed Web of Science ®Google Scholar
• •Two variants of the novel regimen BEACOPP (standard and escalated dose) are compared with COPP/ABVD in 505 patients with advanced Hodgkin's disease. The COPP/ABVD regimen showed significant inferiority in progression rate and freedom from treatment failure compared with the pooled results of both BEACOPP variants (75 vs. 84%).
   Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S et al. of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma [see comments]. N. Engl. Med 328,1002–1006 (1993).
   PubMed Web of Science ®Google Scholar
• ••Fisher et al report on the three-armrandomized trial of CHOP Pro-MACE CytaBOM and MACOP-B in 899 patients with aggressive NHL. The authors found no difference between arms with regard to response rate, time to treatment failure, overall survival and incidence of severe or life-threatening toxicity.
   Google Scholar
• Horning SJ, Rosenberg SA. The natural of initially untreated low-grade non-Hodgkin's lymphomas. N Engl. I Merl 311,1471–1475 (1984).
   PubMed Web of Science ®Google Scholar
• ••Homing et al. studied the natural historyof 83 patients with low-grade NHL They report that neither the time to histologic transformation nor the incidence of transformation was influenced by when therapy was started.
   Google Scholar
• Gallagher CJ, Gregory WM, Jones AE et al. lymphoma: prognostic factors for response and survival. j Gun. Oncol 4, 1470–1480 (1986).
   Google Scholar
• Philip T, Guglielmi C, Hagenbeek A et al bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma [see comments]. N Engif Med. 333,1540–1545 (1995).
   PubMed Web of Science ®Google Scholar
• ••Philip et al. studied 109 patients withchemosensitive relapse. Patients were randomly assigned to receive four courses of chemotherapy plus radiotherapy or radiotherapy plus intensive chemotherapy and autologous bone marrow transplantation. The response rate was 84% after bone marrow transplantation and 44% after chemotherapy without transplantation. At 5-years, the rate of event-free survival was 46% in the transplantation group and 12% in the group receiving chemotherapy without transplantation (P = 0.001) and the rate of overall survival was 53 and 32%, respectively (P = 0.038).
   Google Scholar
• Vose JM, Wahl RL, Saleh M et al. Phase II study of iodine-131 tositumomab for chemotherapy-relapsed/ refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. Clin. Onco1.18, 1316–1323 (2000).
   Google Scholar
• Linch DC, Winfield D, Goldstone AH et al Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet341,1051–1054 (1993).
   PubMed Web of Science ®Google Scholar
• ••The British National LymphomaInvestigation undertook a randomized comparison of high-dose chemotherapy plus ABMT with the same drugs at lower doses not requiring bone-marrow rescue in patients with active Hodgkin's disease, for whom conventional therapy had failed. Both event-free survival and progression-free survival showed significant differences in favour of high-dose chemotherapy plus ABMT.
   Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK et Rituximab chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. I Clin. Onco1.16, 2825–2833 (1998).
   Google Scholar
• •• 166 patients with low-grade NHL were treated with four weekly courses of ritwdmab. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders was 13.0 months. Only 12% of patients had grade 3 and 3% grade 4 toxicities. A human antichimeric antibody was detected in only one patient.
   Google Scholar
• Coiffier B, Haioun C, Ketterer N et al. (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. B/ooc/92, 1927–1932 (1998).
   Google Scholar
• Foran JM, Rohatiner AZ, Cunningham D al European Phase II study of rituximab (chimeric antiCD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma [published erratum appears in J. Clin. Oncol May 18(9), 2006 (2000)1.1 Clin. Oncol 18, 317–324 (2000).
   Google Scholar
• Davis TA, White CA, Grillo-Lopez AJ et al. -agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a Phase II trial of rituximab. j Clin. Oncol 17, 1851–1857 (1999).
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA et al. antiCD20 monoclonal antibody therapy in non-Hodgkin s lymphoma safety and efficacy of re-treatment I ClinOncol 18, 3135–3143 (2000).
   Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric antiCD20 monoclonal antibody and CHOP chemotherapy. I Clin. amyl 17, 268–276 (1999).
   Google Scholar
• Coiffier B, Lepage E, Herbrecht R et al (Rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial. B/ooc/96, 223a (2000).
   Google Scholar
• Kaminski MS, Estes J, Regan D et al. Front- treatment of advanced B-cell low-grade lymphoma (LGL) with radiolabelled antiBl antibody: Initial experience. Proc. Am Soc Glitz Onto]. 16, 51 (1997).
   Google Scholar
• Witzig TE, White CA, Wiseman GA et al. VII trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. I Clin. Onco1.17, 3793–3803 (1999).
   Google Scholar
• Witzig TE, White CA, Gordon LI et al. Final of the zevelin radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL. Hoor196, 831a (2000).
   Google Scholar
• McDonnell TJ, Nunez G, Platt FM et al. Bc1-2-immunoglobulin expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mal Cell. Biol. 10, 1901–1907 (1990).
   Google Scholar
• Hermine O, Haioun C, Lepage E et al. significance of bc1-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). B/ooc/87, 265–272 (1996)
   Google Scholar
• Hill ME, MacLennan IKA, Cunningham et al. Prognostic significance of BCL-2 expression and bc1-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. B/ooc/88, 1046–10451 (1996).
   Google Scholar
• Gascoyne RD, Adomat SA, Krajewski S et al Prognostic significance of Bc1-2 protein expression and Bc1-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. B/ooc/90, 244–251 (1997).
   Google Scholar
• Waters JS, Webb A, Cunningham D et al. I clinical and pharmacokinetic study of bc1-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma [see comments]. I Clin. Onco1.18, 1812–1823 (2000).
   Google Scholar
• Kwak LW Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors [see comments]. N Eng/. Med. 327, 1209–1215 (1992).
   PubMedGoogle Scholar
• Hsu FJ, Caspar CB, Czerwinski D et al. -specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. B/ooc/89, 3129–3135 (1997)
   Google Scholar
• Bendandi M, Kwak LW Translational of patient-specific vaccination for follicular lymphoma. .thematologica 84, 70–72 (1999).
   PubMedGoogle Scholar
• Hagenbeek A, Eghbali H, Monfardini S et Fludarabine versus conventional CVP chemptherapy in newly diagnosed patients with stage III and IV low grade malignant non-Hodgkin's lymphoma. Preliminary results from a prospective, randomized Phase III clinical trial in 381 patients. Blood 92, 1294 (1998)
   Google Scholar
• Klasa R, Conors J, Gascoyne R, Hoskins P, 'Riley S, Shenkier T CPF (cyclophosphamide, prednisone, fludarabine) in advance stage previously low grade mantle cell lymphoma. Blood. 90 (10), 324a.
   Google Scholar
• Coiffier B, Neidhardt-Berard EM, Tilly H al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomas de l'Adulte. Ann. 0=110 (10), 1191-1197
   Google Scholar
• McLaughlin P, Hagemeister FB, JE et al. Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma. Clin. Onco1.14, 1262–1268 (19960.
   Google Scholar
• Hochster HS, Oken MM, Winter JN et al. I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up-a report from the Eastern Co-operative Oncology Group. I Clin. Onco1.18, 987–994 (2000).
   Google Scholar
• Crawley CR, Foran JM, Gupta RIK et al. A II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Ann. Oncol 11(7), 861–865 (2000)
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Cabanillas F, Younes A et al. IV low grade lymphoma (1g1): randomized trial of two innovative regimens, with monitoring of BCL-2 by PCR. Pmc. Am. Soc. Clin. Oncol 7\(Suppl. 3), 34 (1996a).
   Google Scholar
• Foussard C, Deconinck E, Desablens B et A randomized trial of fludarabine, mitoxantrone (FM) versus doxorubicin, cyclophosphamide, vindesine, prednisone (CHEM as first line treatment in patiemnts with advanceed low grade non-Hodgkin's lymphoma (LG-NHL): A multicentre study by GOELAMS group. Blood 92, 316a (1998).
   Google Scholar
• Press OW Livingston R, Mortimer J, C, Appelbaum E Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine and cisplatin before marrow transplantation. Clin. Oncol 9, 423–431 (1991).
   Google Scholar
• Savage DG, Rule SA, Tighe M et al. Gemcitabine for relapsed or resistant lymphoma [In Process Citation]. Ann. Oncol 11, 595–597 (2000).
   PubMed Web of Science ®Google Scholar
• Fossa A, Santoro A, Hiddemann W et al. as a single agent in the of relapsed or refractory aggressive non-Hodgkin's lymphoma. Clin. Oncol 17,3786–3792 (1999).
   Google Scholar
• Zinzani PL, Baliva G, Magagnoli M et al. treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. I Clin. Onco1.18, 2603–2606 (2000).
   Google Scholar
• Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter Phase II study.J Clin. Onco1.18, 2615–2619 (2000).
   Google Scholar
• Chau I, Cunningham D, Hill M, Catovsky . Dexamethasone, cytarabine and oxaliplatin (DHAX) in relapsed or refractory non-Hodgkin's lymphoma patients: Results of an ongoing Phase II trial. B/ooc/96,140a (2000).
   Google Scholar
• Balzarotti M, Santoro A, Tondini C, M, Bonadonna G. Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. Ann. Om& 7(9), 970–972 (1996).
   Google Scholar
• Rule S, Tighe M, Davies S, Johnson S. in the treatment of lymphoma. Hematol 017C0i 16(3), 101–105 (1998).
   Google Scholar
• Rummel MJ, Chow KU, Jager E et al 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle lymphomas. Leuk. Lymphoma 35 (1–2), 129–138 (1999).
   Google Scholar
• Tondini C, Balzarotti M, Rampinelli I et al. and cladribine in relapsed/ refractory low-grade non-Hodgkin's lymphoma: a Phase II randomized study. Ann. 0=111 (2), 231–233 (2000).
   Google Scholar
• Mead G, Sydes M. International evaluation National Cancer Institute Protocol 89-C-41 (with minor modifications) in adults with non-HIV related Burkitt's lymphoma-A United Kingdom Lymphoma Group (UKLG) Study. Proc. Am. Soc. Gun. Om& 18,12a (1999).
   Google Scholar
• Gianni AM, Bregni M, Siena S et al. High- chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N. Engl. I. Merl 336 (18), 1290 (1997).
   Google Scholar
• Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. Clin. Oncol 15,1131–1137 (1997).
   Google Scholar
• Santini G, Salvagno L, Leoni P et al. VACOP-B versusVACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's : results of a prospective randomized trial by the non-Hodgkin's Lymphoma Co-operative Study Group. Clin. Onco1.16, 2796–2802 (1998).
   Google Scholar
• Kluin-Nelemans JC, Zagone V, Thomas J al. Consolidation ABMT after standard chemotherapy vs. CHVmP/BV alone for primary intermediate and high grade NHL: A randomised Phase III EORTC study. Proc. Am. Soc. Clin. Oncol 18,2a (1999).
   Google Scholar
• Reyes F, Lepage E, Morel P et al. Failure of -Line Inductive High-Dose (HDC) in Poor-Risk Patients (PTS) with Aggressive Lymphoma: Updated Results of the Randomised LNH93-3 Study. B/ooc/90\(Suppl. 1), 594a (1997).
   Google Scholar
• Kaiser U, Uelbacker I, Havemann K. High- chemotherapy with autologous stem cell transplantation In high-grade NHL: First analysis of a randomised multicentre study. Bone Marrow 7iamplant. 21 (Suppl. 1), 177 (1998).
   Google Scholar
• Carella AM, Prencipe E, Pungolino E et al. years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy. Leuk. Lymphoma 21(1-2), 63–70 (1996).
   PubMed Web of Science ®Google Scholar